Bluestem Biosciences files 24 patent applications
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Cipla has received 8 inspectional observations in Form 483
There is a fast resurgence in the transplant activities post COVID
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Subscribe To Our Newsletter & Stay Updated